Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
3
×
boston top stories
life sciences
national blog main
biotech
boston
cancer
clinical trials
national top stories
new york blog main
accelerated approval
acute hepatic porphyria
alnylam pharmaceuticals
aminolevulinic acid
arena pharmaceuticals
beam therapeutics
biotech week boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
broad institute
bwb
cardiovascular disease
cindy perettie
colorectal cancer
crispr
david liu
detroit blog main
detroit top stories
drugs
editas medicine
eisai
europe blog main
europe top stories
fda
foundation medicine
givosiran
immuno-oncology
indiana blog main
indiana top stories
What
market
3
×
medicine
3
×
drug
patients
alnylam
benefiting
boston
cancer
cleared
coming
data
diagnostics
eisai
far
fda
flags
glimcher
groundbreaking
headline
higher
incidence
interference
keynote
laurie
lorcaserin
loss
marketing
nasdaq
new
ok
pharmaceuticals
post
precision
promise
pulls
risks
rna
rnai
second
seek
Language
unset
Current search:
market
×
medicine
×
" boston blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
